Life Sciences Tools & Services · Nasdaq

ILMNIllumina, Inc.

Last close
$207.01 -1.2%
52-week range
$112.65 to $309.35
Market cap
$31.3B
Next earnings
Not scheduled

Fiscal 2025 at a glance

Revenue
$4.34B
-1% vs FY24
Net income
$850M
+170% vs FY24
Free cash flow
$931M
+31% vs FY24
Net cash
$143M
Cash $1.63B, debt $1.49B

Stock price

+68% since Dec 2016

Valuation vs its own 10 years

Below its 10-year median on all 4 multiples

Where each multiple sits today inside its own range since 2017, measured at every quarter end. The thin tick is the median.

P/E, trailing
35.6x
12.0x91.2x
25th percentile, below its median of 51.4x
Positive-earnings quarters only
Price / sales
6.9x
2.9x17.6x
40th percentile, below its median of 10.3x
EV / EBITDA
27.3x
10.1x1,142x
21st percentile, below its median of 42.2x
Price / free cash flow
29.6x
14.1x566x
16th percentile, below its median of 55.4x

Key statistics

Trailing 12 months unless noted, through the quarter ending 2026-09-27. Every figure carries its unit.

Valuation

P/E
35.6x
Earnings yield
2.8%
Price / sales
6.9x
Price / book
10.0x
Price / operating cash flow
25.4x
EV / EBITDA
27.3x
EV / sales
7.0x
Free cash flow yield
3.4%

Profitability

Gross margin
67.9%
Operating margin
21.2%
Net margin
19.7%
Return on equity
28.5%
Return on capital
16.5%

Growth per year

Revenue, 3 years
-1.8%
Revenue, 5 years
+6.0%
Revenue, 9 years
+6.8%
EPS, 3 years
n/aNot meaningful (a loss in the window)

Balance sheet

Cash and investments
$1.34B
Total debt
$1.79B
Net cash
-$452M
Debt / equity
0.57x
Current ratio
2.63x

Shares and dividend

Shares outstanding
151M
Share count, 5 years
+5.4%
Beta, 1 year
1.08
Dividend yield
n/a
Dividend per share, TTM
n/a
Payout ratio
n/a

n/a: No dividend

Ten years of the business

Last 40 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.

Revenue and net incomeLatest quarter $1.13B
RevenueNet income
Gross profitLatest quarter $830M
EBITDALatest quarter $357M
Margins74 / 27 / 19%
GrossOperatingNet
Earnings per shareLatest quarter $1.43
Cash flowLatest quarter $419M
OperatingCapexFree
Cash vs debtLatest quarter $1.34B
Cash and investmentsTotal debt
P/E historyNow 35.6x
P/E, median 51.4x dashed
P/S historyNow 6.9x
P/S, median 10.3x dashed

Where the revenue comes from

Instruments went from 16% to 11% of revenue in 3 years

Share of revenue by product line, fiscal 2022 to 2025, as reported in the 10-K.

ConsumablesServicesInstruments
FY22
70%14%16%
$4.58B
FY23
68%16%16%
$4.50B
FY24
72%16%11%
$4.37B
FY25
74%15%11%
$4.34B
Fiscal 2025 by product line
Product lineRevenueSharevs FY24
Consumables$3.23B74.3%+2%
Services$634M14.6%-11%
Instruments$482M11.1%-4%

Life Sciences Tools & Services peers

The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.

CompanyMarket capRevenue growth Operating marginP/EP/SP/E vs own history
TMO Thermo Fisher Scientific Inc. $259B +8% 17.9%36.9x5.5x 88th percentile
A Agilent Technologies, Inc. $49.0B +9% 22.2%34.2x6.7x 64th percentile
WAT Waters Corp $45.2B +81% 4.7%198x8.1x 90th percentile
IQV Iqvia Holdings Inc. $43.7B +9% 12.8%32.2x2.5x 38th percentile
MTD Mettler Toledo International Inc/ $34.6B +7% n/a37.7x8.2x 58th percentile
ILMN Illumina, Inc. $31.3B +6% 21.1%35.6x6.9x 25th percentile

The company

Sector
Health Care
Industry
Life Sciences Tools & Services
Founded
1998
Headquarters
San Diego, CA
Fiscal year ends
Late December
Website
illumina.com

What it does

Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function.

Description from Wikipedia (CC BY-SA).

Around the numbers

What the rest of EdgeStacker knows about ILMN.

Next report

No confirmed report date in the next 95 days yet.

Open the Earnings Hub
Big funds, latest 13F

Held by 648 active funds. Crowd level: quiet.

Open the Smart money tab